Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial.

Notably, patients achieving CR exhibited markedly higher T cell activation immune scores post-treatment compared to those PR patients, demonstrated by a trend toward significance ( P = 0.06, Fig. 5c ).

also in 413 other papers